Tenaya Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Tenaya Therapeutics, Inc. (TNYA) reported Increase (Decrease) in Accounts Payable of -$472.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $988.00K.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.46M.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $531.00K.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$447.00K, a 134.92% decline year-over-year.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.43M.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$581.00K.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$3.28M, a 297.71% decline from fiscal 2022.
- Tenaya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.66M, a 80.70% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $988.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$472.00K 10-Q · filed 2026-08-05 | $59.00K derived: sum of 3 quarters · filed 2026-08-05 | -$388.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.46M 10-Q · filed 2026-05-06 | -$929.00K derived: sum of 2 quarters · filed 2026-05-06 | -$1.38M derived: sum of 3 quarters · filed 2026-05-06 | -$2.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $84.00K derived: sum of 2 quarters · filed 2026-03-11 | -$1.05M derived: sum of 3 quarters · filed 2026-08-05 | -$1.43M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$447.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.58M derived: sum of 2 quarters · filed 2026-08-05 | -$1.96M 10-Q · filed 2025-11-10 | -$2.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.51M 10-Q · filed 2026-08-05 | -$2.21M derived: sum of 3 quarters · filed 2026-08-05 | -$935.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$379.00K 10-Q · filed 2026-05-06 | -$1.08M derived: sum of 2 quarters · filed 2026-05-06 | $200.00K derived: sum of 3 quarters · filed 2026-05-06 | -$2.23M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $579.00K derived: sum of 2 quarters · filed 2026-03-11 | -$1.85M derived: sum of 3 quarters · filed 2026-03-11 | -$581.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.15M derived: sum of 2 quarters · filed 2025-11-10 | $120.00K 10-Q · filed 2025-11-10 | -$185.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.16M 10-Q · filed 2025-08-06 | -$1.47M derived: sum of 3 quarters · filed 2025-08-06 | -$4.22M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-07 | $967.00K derived: sum of 2 quarters · filed 2025-05-07 | -$1.79M derived: sum of 3 quarters · filed 2025-05-07 | -$686.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$3.06M derived: sum of 2 quarters · filed 2025-03-10 | -$1.96M derived: sum of 3 quarters · filed 2025-03-10 | -$3.28M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.65M derived: sum of 2 quarters · filed 2024-11-06 | -$2.98M 10-Q · filed 2024-11-06 | $486.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$223.00K 10-Q · filed 2024-08-08 | $3.24M derived: sum of 3 quarters · filed 2024-08-08 | $3.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.32M 10-Q · filed 2024-05-14 | $2.14M derived: sum of 2 quarters · filed 2024-05-14 | $2.46M derived: sum of 3 quarters · filed 2024-05-14 | $2.12M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $3.78M derived: sum of 2 quarters · filed 2024-03-18 | $3.44M derived: sum of 3 quarters · filed 2024-03-18 | $1.66M 10-K · filed 2024-03-18 |
| 2022-09-30 | $317.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$24.00K derived: sum of 2 quarters · filed 2023-11-08 | -$1.80M 10-Q · filed 2023-11-08 | $4.28M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$341.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.12M 10-Q · filed 2023-08-09 | $3.96M derived: sum of 3 quarters · filed 2023-08-09 | $5.12M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.78M 10-Q · filed 2023-05-10 | $4.30M derived: sum of 2 quarters · filed 2023-05-10 | $5.46M derived: sum of 3 quarters · filed 2023-05-10 | $6.20M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $7.24M derived: sum of 2 quarters · filed 2023-03-08 | $7.98M derived: sum of 3 quarters · filed 2023-03-08 | $8.60M 10-K · filed 2023-03-08 |
| 2021-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.90M derived: sum of 2 quarters · filed 2022-11-10 | $2.52M 10-Q · filed 2022-11-10 | $2.13M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $745.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.36M 10-Q · filed 2022-08-10 | $978.00K derived: sum of 3 quarters · filed 2022-08-10 | $1.08M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $618.00K 10-Q · filed 2022-05-11 | $233.00K derived: sum of 2 quarters · filed 2022-05-11 | $338.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$385.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$280.00K derived: sum of 2 quarters · filed 2022-03-23 | $142.00K 10-K · filed 2022-03-23 | |
| 2020-09-30 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $527.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $422.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |